Difference between revisions of "Lunasin"
From MyWiki
| Line 4: | Line 4: | ||
*''A recent finding is that lunasin may reduce the progressive muscular weakening of ALS. Rick Bedlack, director of Duke University's ALS Clinic in Durham, NC, found a patient, Michael McDuff, who surprisingly was getting better. The cause seemed to be a regimen of lunasin that McDuff started on his own. Currently Bedlack has started a trial with other ALS patients to see if it works for a large clinically-controlled group of patients. A clinical trial is ongoing.'' | *''A recent finding is that lunasin may reduce the progressive muscular weakening of ALS. Rick Bedlack, director of Duke University's ALS Clinic in Durham, NC, found a patient, Michael McDuff, who surprisingly was getting better. The cause seemed to be a regimen of lunasin that McDuff started on his own. Currently Bedlack has started a trial with other ALS patients to see if it works for a large clinically-controlled group of patients. A clinical trial is ongoing.'' | ||
| + | |||
| + | |||
| + | == Effects on ALS == | ||
| + | |||
| + | ''found to exert potent antioxidant properties, reducing lipopolysaccharide induced production of ROS by macrophage cells, and acting as a potent free radical scavenger.'' {{#pmid:25033546|wolosik2014}} | ||
[[Category:Supplement data pages]] | [[Category:Supplement data pages]] | ||
Revision as of 10:05, 7 November 2017
Information on nutritional supplements people with ALS have been taking
- A recent finding is that lunasin may reduce the progressive muscular weakening of ALS. Rick Bedlack, director of Duke University's ALS Clinic in Durham, NC, found a patient, Michael McDuff, who surprisingly was getting better. The cause seemed to be a regimen of lunasin that McDuff started on his own. Currently Bedlack has started a trial with other ALS patients to see if it works for a large clinically-controlled group of patients. A clinical trial is ongoing.
Effects on ALS
found to exert potent antioxidant properties, reducing lipopolysaccharide induced production of ROS by macrophage cells, and acting as a potent free radical scavenger. [1]- ↑ Wołosik et al.: [Lunasin--a novel chemopreventive peptide]. Postepy Biochem. 2014;60:84-9. PMID: 25033546. Lunasin is a bioactive peptide originally isolated from soybean and has demonstrated chemopreventive and anticancer properties against: skin, colon, prostate and breast cancers. Lunasin by binding to the receptors of colon cancer cells prevents its adhesion to the liver tissue. When the receptor is blocked, new blood vessels cannot differentiate which prevent the spread of cancer. In the model estrogen-independent breast cancer, lunasin and aspirin administration inhibits cell proliferation, arrest cell cycle in S-phase as well as a decreases expression of cancer genes. Lunasin has also been found to exert potent antioxidant properties, reducing lipopolysaccharide induced production of ROS by macrophage cells, and acting as a potent free radical scavenger. Using the modifying the of DNA method it has been demonstrated that CpG islands were hypomethylated in RWPE-1 cell lines and hypermethylated RWPE-2 in cell line.Despite of numerous and promising evidence of antitumor activity of lunasin, there are still not explained all the mechanisms of its action in the processes of carcinogenesis.
